PMID- 26482899
OWN - NLM
STAT- MEDLINE
DCOM- 20160421
LR  - 20181113
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 15
DP  - 2015 Oct 20
TI  - Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker 
      in patients with laryngeal squamous cell carcinoma.
PG  - 743
LID - 10.1186/s12885-015-1727-6 [doi]
LID - 743
AB  - BACKGROUND: Neutrophil-lymphocyte ratio (NLR) has been shown to be associated 
      with prognosis in various solid tumors. This study aimed to evaluate the 
      prognostic role of NLR in patients with laryngeal squamous cell carcinoma (LSCC). 
      METHODS: A total of 141 LSCC patients were retrospectively reviewed. Patients' 
      demographics were analyzed along with clinical and pathologic data. The optimal 
      cutoff value of NLR was determined using receiver operating characteristic (ROC) 
      curve analysis. The impact of the NLR and other potential prognostic factors on 
      disease-free survival (DFS) and overall survival (OS) was assessed using the 
      Kaplan-Meier method and multivariate Cox regression analysis. RESULTS: The 
      optimal cutoff value of the NLR was 2.17. In the NLR </= 2.17 group, the 1-, 3-, 
      and 5-year DFS rates were 88.2, 73.9 and 69.1 %, respectively, while in the NLR > 
      2.17 group, the DFS rates were 83.0, 54.6 and 49.2 %, respectively. 
      Correspondingly, the 1-, 3-, and 5-year OS rates were 98.9, 85.1 and 77.4 % in 
      the NLR </= 2.17 group and 97.9, 63.8 and 53.3 % in the NLR > 2.17 group, 
      respectively. The multivariate Cox proportional hazard model analysis showed that 
      NLR > 2.17 was a prognostic factor for both DFS [hazard ratio (HR) = 1.869; 95 % 
      confidence interval (CI) 1.078-3.243; P = 0.026] and OS (HR =2.177; 95 % CI 
      1.208-3.924; P = 0.010). CONCLUSION: Our results showed that elevated 
      preoperative NLR was an independent predictor of poor prognosis for patients with 
      LSCC after surgical resection.
FAU - Tu, Xiu-Ping
AU  - Tu XP
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, Guangdong, 510080, P. R. China. 
      tuxiuping105@163.com.
FAU - Qiu, Qian-Hui
AU  - Qiu QH
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, Guangdong, 510080, P. R. China. 
      qiuqianhui@hotmail.com.
FAU - Chen, Liang-Si
AU  - Chen LS
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, Guangdong, 510080, P. R. China. 
      lancer_chen@hotmail.com.
FAU - Luo, Xiao-Ning
AU  - Luo XN
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, Guangdong, 510080, P. R. China. 
      luoxn_ent@126.com.
FAU - Lu, Zhong-Ming
AU  - Lu ZM
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, Guangdong, 510080, P. R. China. entlu@126.com.
FAU - Zhang, Si-Yi
AU  - Zhang SY
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, Guangdong, 510080, P. R. China. 
      szhang555@hotmail.com.
FAU - Chen, Shao-Hua
AU  - Chen SH
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, Guangdong, 510080, P. R. China. 
      chenshaohua1168@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151020
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/mortality/*pathology/surgery
MH  - China/epidemiology
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/mortality/*pathology/surgery
MH  - Lymphocytes/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/*pathology
MH  - Preoperative Period
MH  - Prognosis
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Survival Rate/trends
PMC - PMC4615885
EDAT- 2015/10/21 06:00
MHDA- 2016/04/22 06:00
PMCR- 2015/10/20
CRDT- 2015/10/21 06:00
PHST- 2015/01/21 00:00 [received]
PHST- 2015/10/08 00:00 [accepted]
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2016/04/22 06:00 [medline]
PHST- 2015/10/20 00:00 [pmc-release]
AID - 10.1186/s12885-015-1727-6 [pii]
AID - 1727 [pii]
AID - 10.1186/s12885-015-1727-6 [doi]
PST - epublish
SO  - BMC Cancer. 2015 Oct 20;15:743. doi: 10.1186/s12885-015-1727-6.